1 day Ago By Defense World Staff
Checkpoint Therapeutics ( NASDAQ:CKPT – Get Free Report ) ‘s stock had its “buy” rating reiterated by HC Wainwright in a note issued to investors on Monday, Benzinga reports. They currently have a $20.00 price target on the stock.
Checkpoint Therapeutics Price Performance CKPT stock opened at $2.52 on Monday. The firm’s fifty day simple moving average is $2.
32 and its 200-day simple moving average is $2.03. Checkpoint Therapeutics has a 12 month low of $1.
30 and a 12 month high of $3.62. The company has a market capitalization of $89.
93 million, a P/E ratio of -0.91 and a beta of 1.29.
Checkpoint Therapeutics ( NASDAQ:CKPT – Get Free Report ) last announced its quarterly earnings results on Monday, August 12th. The company reported ($0.18) earnings per share for the quarter, beating the consensus estimate of ($0.
29) by $0.11. The company had revenue of $0.
04 million for the quarter. As a group, sell-side analysts forecast that Checkpoint Therapeutics will post -0.81 earnings per share for the current year.
Insider Transactions at Checkpoint Therapeutics Institutional Inflows and Outflows Large investors have recently bought and sold shares of the stock. Armistice Capital LLC raised its stake in shares of Checkpoint Therapeutics by 17.5% in the 4th quarter.
Armistice Capital LLC now owns 2,426,000 shares of the company’s stock valued at $5,556,000 after acquiring an additional 362,000 shares during the period. Vanguard Group Inc. raised its position in Checkpoint Therapeutics by 67.
4% in the first quarter. Vanguard Group Inc. now owns 917,894 shares of the company’s stock valued at $1,882,000 after purchasing an additional 369,586 shares during the period.
B. Riley Wealth Advisors Inc. raised its position in Checkpoint Therapeutics by 366.
3% in the second quarter. B. Riley Wealth Advisors Inc.
now owns 229,200 shares of the company’s stock valued at $493,000 after purchasing an additional 180,050 shares during the period. PVG Asset Management Corp acquired a new position in Checkpoint Therapeutics during the second quarter worth $295,000. Finally, Choreo LLC boosted its position in shares of Checkpoint Therapeutics by 12.
2% during the second quarter. Choreo LLC now owns 65,002 shares of the company’s stock worth $133,000 after buying an additional 7,080 shares during the period. Institutional investors and hedge funds own 22.
00% of the company’s stock. About Checkpoint Therapeutics ( Get Free Report ) Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.
Featured Stories Five stocks we like better than Checkpoint Therapeutics Why Are Stock Sectors Important to Successful Investing? Galmed Pharmaceuticals Surges 400%: What’s Behind the Explosion? Why Invest in High-Yield Dividend Stocks? Gold Hits New All-Time Highs: 3 Stocks to Ride the Surge What is a Special Dividend? Intel: Why It’s Time to Reconsider This Beaten-Down Chipmaker Receive News & Ratings for Checkpoint Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Checkpoint Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter ..
